Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Metformin May Delay Aging and Cancer Progression

Metformin delays aging and cancer progression by reducing the production of....
Advertisement

A research team from the University of Montreal revealed the mechanism of how metformin slows aging and cancer progression. In a study, they found that metformin reduces the production of inflammatory cytokines. These inflammatory cytokines are key players activating the immune system in tissue damage during aging and tumor growth in cancer development.

Dr. Gerardo Ferbeyre and colleagues found that metformin decreases cytokines by disrupting a protein called NF-kB that would normally trigger cytokine activation and the immune system. When cytokines are overproduced, this leads to pathological inflammation that is involved in both the aging and cancer processes.

Dr. Ferbeyre said, "This is an important finding with implications for our understanding on how the normal organism defends itself from the threat of cancer and how a very common and safe drug may aid in treatment of some cancers and perhaps slow down the aging process." He added, "It remains that determining the specific targets of metformin would give us an even better opportunity of profit from its beneficial effects. That's what we want to figure out next." This finding may be an important step in finding a place for metformin therapy in anti-cancer and anti-aging therapy.

"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-B activation" Aging Cell, March 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Past five issues: Issue 774 | Diabetes Clinical Mastery Series Issue 233 | SGLT-2 Inhibitors Special Edition March 2015 | Issue 773 | Diabetes Clinical Mastery Series Issue 232 |

2015 Most Popular Articles:

FDA Approves Sanofi's Diabetes Drug Toujeo
Posted February 27, 2015
One Modification of Diet Can Improve the Metabolic Syndrome
Posted February 27, 2015
Eylea Bests Avastin, Lucentis in Diabetic Macular Edema
Posted February 27, 2015
'Smart' Insulin Holds Promise for Type 1 Diabetes Patients
Posted February 27, 2015
What Most Docs Don't Do: Counsel Patients on Drug Adherence
Posted February 27, 2015
Reduced GLP-1 Precedes Type 2 Diabetes
Posted March 05, 2015
Resistance Exercise after Dinner Decreases CVD Risk for Type 2's
Posted February 27, 2015
Breastfeeding May Lower Risk of Type 1 Diabetes
Posted February 27, 2015
Quality Management in Diabetes Care
Posted February 27, 2015
Breakfast Habits Affect Overweight Teen Girls Metabolic Responses to Protein-Packed Morning Meals
Posted March 13, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are you interested in learning how to improve patient care by doing a reimbursable comprehensive diabetic foot exam?
CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control